(259 days)
No
The description focuses on the physical characteristics and intended use of a hemodialysis catheter, with no mention of AI or ML.
Yes
The device is a hemodialysis catheter used to attain long-term vascular access for chronic hemodialysis and apheresis, which are therapeutic medical procedures.
No
The provided text describes a hemodialysis catheter, which is used for treatment (vascular access for hemodialysis and apheresis), not for diagnosing a condition.
No
The device description clearly outlines a physical catheter made of polyurethane with accessories for insertion, indicating it is a hardware medical device, not software-only.
Based on the provided text, the NexSite™ HD, Hemodialysis Catheter for long term use is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "attaining long term vascular access for chronic hemodialysis and apheresis." This is a procedure performed directly on a patient's body to access their bloodstream for treatment.
- Device Description: The device is a catheter designed to be inserted into veins (internal jugular, subclavian, femoral). It is a physical device used for accessing the circulatory system.
- Lack of IVD Characteristics: IVD devices are used to examine specimens (like blood, urine, tissue) outside of the body to provide information about a person's health. The description of the NexSite HD does not involve any such testing or analysis of specimens.
Therefore, the NexSite HD is a medical device used for a therapeutic procedure (hemodialysis/apheresis) by providing vascular access, not an IVD device used for diagnostic testing of specimens.
N/A
Intended Use / Indications for Use
The NexSite™ HD, Hemodialysis Catheter for long term use is indicated for use in attaining long term vascular access for chronic hemodialysis and apheresis. It may be inserted percutaneously and is primarily placed in the internal jugular vein of an adult patient. Alternate insertion sites include the subclavian vein. Catheters greater than 40cm long are intended for femoral vein insertion.
Product codes
MSD
Device Description
The NexSite HD (55 cm), Hemodialysis Catheter for long term use is a long term catheter intended for use in attaining long term vascular access for hemodialysis and apheresis. The NexSite HD, Hemodialysis Catheter for long term use is available in a range of lengths up to 55cm. The NexSite HD (55cm) Hemodialysis Catheter is manufactured from polyurethane and has a Dacron cuff distal to the bifurcation junction. A Polyurethane/Dacron Dermal Ingrowth Support Collar (DISC) supplied with the Catheter is implanted subcutaneously, and is intended to minimize Catheter movement. The Catheter and DISC are provided with accessories (stainless steel Tunneler and Sleeve, 0.038" Guidewire, 16Fr Introducer/Dilator, Coring Scalpel and Luer Caps) that are used to facilitate catheter placement.
The NexSite HD (55 cm) Hemodialysis Catheter for long term use is provided as a sterile, singleuse device, and is sterilized using a validated ethylene oxide process. The NexSite HD (55 cm) Hemodialysis Catheter for long term use is a blood contact device with greater than 30 days of exposure
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
internal jugular vein, subclavian vein, femoral vein
Indicated Patient Age Range
adult patient
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
In vitro testing was performed on the NexSite HD, Hemodialysis Catheter for long term use to assure reliable design and performance in accordance with ISO 10555-1:2004. The materials and manufacturing processes used in the proposed NexSite HD device for femoral access are identical to those used in the manufacture of cleared NexSite HD devices (K121933 / K133796). Therefore most of the performance testing completed for the cleared NexSite HD device are applicable to the proposed NexSite HD device for femoral access and as such testing was not repeated. The testing specifically performed on the NexSite HD device for femoral access includes a visual and dimensional analysis, priming volume, and catheter pressure vs. flow testing. The results demonstrate that the NexSite HD device (55cm) hemodialysis catheter meets the requirements in the applicable standards and specifications, and is substantially equivalent to legally marketed predicate devices.
In vivo implantation studies were performed on the NexSite HD hemodialysis catheter for long term use to demonstrate that the device would perform as intended. Clinical studies were not deemed necessary since in vivo and in vitro testing were sufficient to demonstrate safety and effectiveness by way of comparison to a legally marketed predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5540 Blood access device and accessories.
(a)
Identification. A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device.
(2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle).
(3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).
(b)
Classification. (1) Class II (special controls) for the implanted blood access device. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.
(ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated.
(B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided.
(C) Priming volumes must be established.
(D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use.
(E) Air leakage testing and liquid leakage testing must be conducted.
(F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage.
(G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern.
(H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established.
(iii) Performance data must demonstrate the sterility of the device.
(iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing.
(v) Labeling of implanted blood access devices for hemodialysis must include the following:
(A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated.
(B) Labeling must specify the forward and reverse recirculation rates.
(C) Labeling must provide the arterial and venous priming volumes.
(D) Labeling must specify an expiration date.
(E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device.
(F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient.
(G) Labeling must include a patient implant card.
(H) The labeling must contain comprehensive instructions for the following:
(
1 ) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;(
2 ) Proper care and maintenance of the device and device exit site;(
3 ) Removal of the device;(
4 ) Anticoagulation;(
5 ) Management of obstruction and thrombus formation; and(
6 ) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following:
(A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port.
(B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following:
(A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied.
(B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties.
(C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens.
(D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness.
(viii) The following must be included for A-V shunt cannulae (with vessel tips):
(A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply.
(B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(2) Class II (performance standards) for the nonimplanted blood access device.
(3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section.
(4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are simple and abstract, and they are the most prominent element of the logo.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 13, 2014
Marvao Medical Devices, Ltd. Christine Nichols, RAC Regulatory Affairs Manager Boston Biomedical Associates 100 Crowley Drive, Suite 216 Marlboro, MA 01752
Re: K140492
Trade/Device Name: NexSite™ HD, Hemodialysis Catheter for long term use Regulation Number: 21 CFR§ 876.5540 Regulation Name: Blood access device and accessories Regulatory Class: II Product Code: MSD Dated: October 8, 2014 Received: October 9, 2014
Dear Christine Nichols,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
1
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Image /page/1/Picture/6 description: The image shows the name "Benjamin R. Fisher -A" in a large, bold font. The text is black and appears to be centered on a white background. The letters are clearly legible, and the overall impression is clean and professional.
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
INDICATIONS FOR USE STATEMENT
| 510(k)
Number (if
| known): | K140492 |
|---|---|
| Device | |
| Name: | NexSite™ HD, Hemodialysis Catheter for long term use |
| Indications | |
| for Use: | The NexSite™ HD, Hemodialysis Catheter for long term use is indicated for use |
| in attaining long term vascular access for chronic hemodialysis and apheresis. It | |
| may be inserted percutaneously and is primarily placed in the internal jugular | |
| vein of an adult patient. Alternate insertion sites include the subclavian vein. | |
| Catheters greater than 40cm long are intended for femoral vein insertion. |
Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (Per 21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
3
510(K) SUMMARY
This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) summary is provided in conformance with 21CFR Part 807.92.
I. SUBMITTER
| Name: | Marvao Medical Devices, Ltd. | |
|---|---|---|
| Address: | GMIT Innovation in Business Centre, Dublin Road | |
| Galway, Ireland | ||
| Phone: | +353 (0)91 759 301 | |
| Fax: | +353 (0)91 762 055 | |
| Contact Person: | Christine Nichols RAC | |
| Boston Biomedical Associates | ||
| 386 West Main Street, Suite 7 | ||
| Northborough, MA 01532 | ||
| cnichols@boston-biomedical.com | ||
| Phone: (508) 691-7046 | ||
| Fax: (508) 351-8637 | ||
| II. DEVICE | ||
| Device/Trade Name: | ||
| Date of Preparation: | ||
| Common Name: | ||
| Classification Name: | ||
| Classification Number: | ||
| Product Code/ Classification Panel: | NexSite HD, Hemodialysis Catheter for long term use | |
| (55 cm) | ||
| November 12, 2014 | ||
| Blood access devices and accessories | ||
| catheter, hemodialysis, implanted | ||
| 876.5540 | ||
| MSD/Gastroenterology /Urology | ||
| III. PREDICATE DEVICES | ||
| K030502 | ||
| K121933 / K133796 | Medcomp® Hemo-Flow® Long Term Hemodialysis | |
| Catheter, Manufactured by Medcomp | ||
| Marvao NexSite HD Hemodialysis Catheter for long | ||
| term use, Manufactured by Marvao Medical | ||
| Devices, Ltd. | ||
| IV. DEVICE DESCRIPTION |
The NexSite HD (55 cm), Hemodialysis Catheter for long term use is a long term catheter intended for use in attaining long term vascular access for hemodialysis and apheresis. The NexSite HD, Hemodialysis Catheter for long term use is available in a range of lengths up to 55cm. The NexSite HD (55cm) Hemodialysis Catheter is manufactured from polyurethane and
4
has a Dacron cuff distal to the bifurcation junction. A Polyurethane/Dacron Dermal Ingrowth Support Collar (DISC) supplied with the Catheter is implanted subcutaneously, and is intended to minimize Catheter movement. The Catheter and DISC are provided with accessories (stainless steel Tunneler and Sleeve, 0.038" Guidewire, 16Fr Introducer/Dilator, Coring Scalpel and Luer Caps) that are used to facilitate catheter placement.
The NexSite HD (55 cm) Hemodialysis Catheter for long term use is provided as a sterile, singleuse device, and is sterilized using a validated ethylene oxide process. The NexSite HD (55 cm) Hemodialysis Catheter for long term use is a blood contact device with greater than 30 days of exposure
V. INTENDED USE
The NexSite™ HD, Hemodialysis Catheter for long term use is indicated for use in attaining long term vascular access for chronic hemodialysis and apheresis. It may be inserted percutaneously and is primarily placed in the internal jugular vein of an adult patient. Alternate insertion sites include the subclavian vein. Catheters greater than 40cm long are intended for femoral vein insertion.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICES
Comparison testing was performed on pre-defined characteristics using finished NexSite™ HD devices and commercial predicate devices. The test results support the substantial equivalence of the NexSite™ HD device to the predicate devices.
VII. PERFORMANCE DATA
In vitro testing was performed on the NexSite HD, Hemodialysis Catheter for long term use to assure reliable design and performance in accordance with ISO 10555-1:2004. The materials and manufacturing processes used in the proposed NexSite HD device for femoral access are identical to those used in the manufacture of cleared NexSite HD devices (K121933 / K133796). Therefore most of the performance testing completed for the cleared NexSite HD device are applicable to the proposed NexSite HD device for femoral access and as such testing was not repeated. The testing specifically performed on the NexSite HD device for femoral access includes a visual and dimensional analysis, priming volume, and catheter pressure vs. flow testing. The results demonstrate that the NexSite HD device (55cm) hemodialysis catheter meets the requirements in the applicable standards and specifications, and is substantially equivalent to legally marketed predicate devices.
In vivo implantation studies were performed on the NexSite HD hemodialysis catheter for long term use to demonstrate that the device would perform as intended. Clinical studies were not deemed necessary since in vivo and in vitro testing were sufficient to demonstrate safety and effectiveness by way of comparison to a legally marketed predicate device.
5
Guidance
The FDA Guidance on Premarket Notification [(510(k)] Submission for Short-Term and Long-Term Intravascular Catheters, dated 3/16/95, was utilized in order to meet the FDA requirements for content and organization of this submission, as well as the Draft Guidance Industry and Food and Drug Administration Staff Implanted Blood Access Devices for Hemodialysis, June 28, 2013.
VIII. CONCLUSIONS
Marvao Medical believes the NexSite HD (55cm) Hemodialysis Catheter for long term use is substantially equivalent to the predicate products. The indications for use, methods of operation, design and materials used are either identical or substantially equivalent to existing legally marketed predicate products.